In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus

Diagnostic Microbiology and Infectious Disease

Volumn 36, Issue 1, 2000, Pages 37-41

  You, Il ^a   Kariyama, Reiko ^b   Zervos, Marcus J ^c   Kumon, Hiromi ^b   Chow, Joseph W ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; HABEKACIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING; STAPHYLOCOCCUS AUREUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BASE SEQUENCE; DIBEKACIN; DNA, BACTERIAL; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; GENTAMICINS; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0033968972     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00104-2     Document Type: Article

References (37)

1. Aoki Y., Kashiwagi H. Bactericidal activity of vancomycin against methicillin-resistant Staphylococcus aureus (MRSA)comparison with minocycline and ofloxacin within therapeutic levels, and factors determining their efficacy. Chemotherapy. 40:1992;997-1004.
2. Aoki Y. Bactericidal activity of arbekacin against methicillin-resistant Staphylococcus aureuscomparison with that of vancomycin. Jap J Antibiotics. 47:1994;640-646.
3. Aoki Y., Yamauchi Y., Hayashi H., Takayama Y., Tsuji A. Characterization of small colony variants of methicillin-resistant Staphylococcus aureus regrown in the presence of arbekacin. J Infect Chemother. 4:1998;107-111.
4. CDC. (1997). Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR 46, 765-766.
5. CDC. (1997). Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR 46, 813-815.
6. Chow J.W., Zervos M.J., Lerner S.A., Thal L.A., Donabedian S.M., Jaworski D.D., Tsai S., Shaw K.J., Clewell D.B. A novel gentamicin resistance gene in Enterococcus. Antimicrob Agents Chemother. 41:1997;511-514.
7. Donabedian S.M., Chow J.W., Shlaes D.M., Green M., Zervos M.J. DNA hybridization and contour-clamped homogeneous electric field electrophoresis for identification of enterococci to the species level. J Clin Microbiol. 33:1995;141-145.
8. Ferretti J.J., Gilmore K.S., Courvalin P. Nucleotide sequence analysis of the gene specifying the bifunctional 6′-aminoglycoside acetyltransferase 2″-aminoglycoside phosphotransferase enzyme in Streptococcus faecalis and identification and cloning of gene regions specifying the two activities. J Bacteriol. 167:1986;631-638.
9. Hamilton-Miller J.M.T., Shah S. Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 35:1995;865-868.
10. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136.
11. Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resistance Updates. 1:1998;135-150.
12. Hotta K., Zhu C.B., Ogata T., Sunada A., Ishikawa J., Mizuno S. Enzymatic 2″-N-acetylation of arbekacin and antibiotic activity of its product. J Antibiotics. 49:1996;458-464.
13. Inoue M., Nonoyama M., Okamoto R., Ida T. Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic, against methicillin-resistant Staphylococcus aureus. Drugs Exp Clin Res. 22:1994;233-240.
14. Kariyama R., Kumon H., Chow L., Zervos M.J., Takata T., Tabata M., Chow J.W. In-vitro activity of the combination of ampicillin and arbekacin against high-level gentamicin-resistant enterococci. J Antimicrob Chemother. 42:1998;836-838.
15. Knapp, C. & Moody, J. A. (1992). Tests to assess bactericidal activity. In: Clinical Microbiology Procedures Handbook, vol 1. Ed, HD Isenberg. Washington, DC: American Society for Microbiology, pp15.16.21-15.16.29.
16. Kondo S., Iinuma K., Yamamoto H., Maeda K., Umezawa H. Syntheses of 1-N-{(S)-4-amino-2-hydroxybutyryl}-kanamycin B and -3′,4′-dideoxykanamycin B active against kanamycin-resistant bacteria. J Antibiotics. 26:1973;412-415.
17. Kondo S., Tamura A., Gomi S., Ikeda Y., Takeuchi T., Mitsuhashi S. Structures of enzymatically modified products of arbekacin by methicillin-resistant Staphylococcus aureus. J Antibiotics. 46:1993;310-315.
18. Leclercq R., Dutka-Malen S., Brisson-Noël A., Molinas C., Derlot E., Arthur M., Duval J., Courvalin P. Resistance of enterococci to aminoglycosides and glycopeptides. Clin Infect Dis. 15:1992;495-501.
19. Levine D.P., Fromm B.S., Reddy B.R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Int Med. 115:1991;739-741.
20. Lewis L.A., Li K., Bharosay M., Cannella M., Jorgenson V., Thomas R., Pena D., Velez M., Pereira B., Sassine A. Characterization of gentamicin-resistant respiratory-deficient (res-) variant strains of Staphylococcus aureus. Microbiol Immunol. 34:1990;587-605.
21. Mulazimoglu L., Drenning S.D., Muder R.R. Vancomycin-gentamicin synergism revisited effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus . Antimicrob Agents Chemother. 40:1996;1534-1535.
22. Mulligan M.E., Murray-Leisure K., Ribner B.S., Standiford H.C., John J.F., Korvick J.A., Kauffman C.A., Yu V.L. Methicillin-resistant Staphylococcus aureus a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management . Am J Med. 94:1993;313-328.
23. Murray B.E. Diversity among multidrug-resistant enterococci. Emerg Infect Dis. 4:1998;37-47.
24. th ed. Villanova, PA: NCCLS.
25. Osakabe Y., Takahashi Y., Narihara K. The utility and dosage and administration of arbekacin in patients with MRSA infection. Antibiotics Chemother. 12:1996;120-127.
26. Panlilio A.L., Culver D.H., Gaynes R.P., Banerjee S., Henderson T.S., Tolson J.S., Martone W.J. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol. 13:1992;582-586.
27. Proctor R.A., Peters G. Small colony variants in staphylococcal infections Diagnostic and therapeutic implications . Clin Infect Dis. 27:1998;419-422.
28. Rouch D.A., Byrne M.E., Kong Y.C., Skurray R.A. The aacA-aphD gentamicin and kanamycin resistance determinant of Tn 4001 from Staphylococcus aureus expression and sequence analysis . J Gen Microbiol. 133:1987;3039-3052.
29. Schaberg D.R., Zervos M.J. Intergeneric and interspecies gene exchange in gram-positive cocci. Antimicrob Agents Chemother. 30:1986;817-822.
30. Suzuki T., Fujita K.I., Nagamachi Y. Emergence of arbekacin resistant strains among methicillin-resistant Staphylococcus aureus. Jap J Antibiotics. 47:1994;634-639.
31. Tenover F.C., Lancaster M.V., Hill B.C., Steward C.D., Stocker S.A., Hancock G.A., O'Hara C.M., McAllister S.K., Clark N.C., Hiramatsu K. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol. 36:1998;1020-1027.
32. Thal L.A., Chow J.W., Patterson J.E., Perri M.B., Donabedian S., Clewell D.B., Zervos M.J. Molecular characterization of highly gentamicin-resistant Enterococcus faecalis isolates lacking high-level streptomycin resistance. Antimicrob Agents Chemother. 37:1993;134-137.
33. Aminoglycoside Resistance Study Group . The most frequently occurring aminoglycoside resistance mechanismscombined results of surveys in eight regions of the world. J Chemother. 7:(suppl 2):1995;17-30.
34. Tsai S.F., Zervos M.J., Clewell D.B., Donabedian S.M., Sahm D.F., Chow J.W. A new high-level gentamicin resistance gene. aph(2″)-Id, in Enterococcus sp. Antimicrob Agents Chemother. 42:1998;1229-1232.
35. Watanabe T., Ohashi K., Matsui K., Kubota T. Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 39:1997;471-476.
36. Wirth R., An F.Y., Clewell D.B. Highly efficient protoplast transformation system for Streptococcus faecalis and a new Escherichia coli-S. faecalis shuttle vector. J Bacteriol. 165:1986;831-836.
37. Yamamoto T., Koyama M., Nakagawa K. Phase-one clinical study on habekacin. Chemotherapy. 34:(Suppl.1):1986;104-116.